Yuxuan Wang, MD, PhD; Lu Li, PhD; Joshua D. Cohen, MPhil; et al.
free access
has audio
JAMA Oncol. 2019;5(8):1118-1123. doi:10.1001/jamaoncol.2019.0512
This study examines the prognostic utility and advantages of ctDNA analysis in all 3 stages of nonmetastatic colorectal cancer.
-
Podcast:
Prognostic Potential of Circulating Tumor DNA Measurement in Nonmetastatic Colorectal Cancer
Thomas Reinert, PhD; Tenna Vesterman Henriksen, MSc; Emil Christensen, PhD; et al.
open access
JAMA Oncol. 2019;5(8):1124-1131. doi:10.1001/jamaoncol.2019.0528
This cohort study investigates the use of longitudinal data from ultradeep sequencing of cell-free DNA in Danish patients with colorectal cancer.
Shaveta Vinayak, MD, MS; Sara M. Tolaney, MD, MPH; Lee Schwartzberg, MD; et al.
open access
JAMA Oncol. 2019;5(8):1132-1140. doi:10.1001/jamaoncol.2019.1029
This open-label phase 2 clinical trial evaluates the clinical activity and safety of combination niraparib and pembrolizumab treatment in women with advanced or metastatic triple-negative breast cancer.
Panagiotis A. Konstantinopoulos, MD, PhD; Steven Waggoner, MD; Gregory A. Vidal, MD; et al.
open access
JAMA Oncol. 2019;5(8):1141-1149. doi:10.1001/jamaoncol.2019.1048
This open-label, single-arm, phases 1 and 2 study evaluates the poly(adenosine diphosphate鈥搑ibose) polymerase inhibitor niraparib combined with pembrolizumab in patients with recurrent ovarian carcinoma.
Philip J. Lupo, PhD; Jeremy M. Schraw, PhD; Tania A. Desrosiers, PhD; et al.
free access
JAMA Oncol. 2019;5(8):1150-1158. doi:10.1001/jamaoncol.2019.1215
This population-based study links data registries on births, birth defects, and cancer diagnoses in 10 million live births in 4 US states to identify associations between birth defects and childhood cancer diagnoses and to characterize cancer risk in children with 1 or more birth defects.
-
Editorial
Birth Defects and Cancer in Childhood鈥擠ual Diseases of Development
Logan G. Spector, PhD; Andrew F. Olshan, PhD
JAMA Oncol
Gerhardt Attard, MD, PhD; Axel S Merseburger, MD; Wiebke Arlt, MD, DSc; et al.
open access
JAMA Oncol. 2019;5(8):1159-1167. doi:10.1001/jamaoncol.2019.1011
This open-label, phase 2 randomized clinical trial assesses the safety of abiraterone acetate combined with 4 glucocorticoid regimens for treatment of metastatic castration-resistant prostate cancer.
-
Invited Commentary
Ideal Glucocorticoid Regimen With Abiraterone Acetate: Options and Challenges
Umang Swami, MD; Sumanta K. Pal, MD; Neeraj Agarwal, MD
JAMA Oncol
Barbara Burtness, MD; Robert Haddad, MD; José Dinis, MD; et al.
free access
JAMA Oncol. 2019;5(8):1170-1180. doi:10.1001/jamaoncol.2019.1146
This randomized clinical trial assesses the effect of afatinib vs placebo after definitive chemoradiotherapy on disease-free survival in patients with head and neck squamous cell carcinoma.
Elizabeth C. Smyth, MD; Samuel Rowley, MSc; Fay H. Cafferty, PhD; et al.
open access
JAMA Oncol. 2019;5(8):1181-1187. doi:10.1001/jamaoncol.2019.1179
This phase 2 randomized clinical trial investigates the effects of adding lapatinib to perioperative epirubicin, cisplatin, and capecitabine chemotherapy in patients with potentially curable HER2-positive gastroesophageal adenocarcinoma.
Ronak Saluja, BSc; Louis Everest; Sierra Cheng; et al.
free access
JAMA Oncol. 2019;5(8):1188-1194. doi:10.1001/jamaoncol.2019.0818
This evidence review and meta-analysis compares the measurement of survival efficacy components of the American Society of Clinical Oncology and European Society for Medical Oncology value frameworks with measures of absolute vs relative survival benefit.
Steve Lu; Julie E. Stein, MD; David L. Rimm, MD, PhD; et al.
free access
JAMA Oncol. 2019;5(8):1195-1204. doi:10.1001/jamaoncol.2019.1549
This systematic review and meta-analysis assesses the diagnostic accuracy of PD-L1 immunohistochemistry, tumor mutational burden, gene expression profiling, and multiplex immunohistochemistry/immunofluorescence assays for determining treatment response to PD-1/PD-L1 checkpoint blockade.
Subha Perni, MD; Michael K. Rooney, BA; David P. Horowitz, MD; et al.
free access
online only
JAMA Oncol. 2019;5(8):e190260. doi:10.1001/jamaoncol.2019.0260
This survey study assesses the readability grade levels of patient informed consent forms used by 89 academic radiation oncology departments across the United States.